Stanford – Estrogen-Only MHT Tied to Lower Alzheimer's Pathology (Neurology, Aug 12 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: Stanford Medicine news release (study: Neurology, American Academy of Neurology) · Published: August 12, 2026 · Accessed: August 13, 2026

Visit the source ↗

Claims this source supports

• Estrogen-only menopausal hormone therapy (MHT) use was associated with 35% lower odds of Alzheimer's disease pathology in autopsied brains – the first study to measure MHT against Alzheimer's hallmarks in substantial numbers of postmortem brains (Stanford Medicine, Neurology, Aug 12 2026).
• Estrogen-only MHT users had 39% lower odds than non-users of receiving a clinical diagnosis of dementia during their lifetimes, and performed better on memory tests and in overall ability to function independently.
• The study analyzed two existing databases totaling 21,462 participants: 258 brain autopsies of women who had used estrogen-only MHT vs ~2,701 women with no MHT use, scored for amyloid plaques and neurofibrillary tangles (plus plaque density).
• The association was statistically significant but modest: investigators describe it as 'modest but meaningful,' and less powerful than age, APOE4, or hypertension as risk factors. Findings adjusted for age, APOE4, hypertension, education, and race.
• Estrogen-only regimens are generally prescribed for women without a uterus (post-hysterectomy; >30% of women by age 60), so the finding's direct implications apply to roughly one-third of menopausal-age women.
• The study could not draw conclusions about estrogen-plus-progestin (combined) regimens – the number of autopsied women on combined therapy was too small. This is an observational association, not proof of causation, and it contrasts with earlier studies that reported MHT raises dementia risk.
• Evidence from living participants' cerebrospinal fluid and blood samples supported the autopsy findings.